WIN 2014: Two Days Dedicated To New Approaches To Personalized Medicine

Posted: Tuesday, July 01, 2014

Winning combinations for precision cancer medicine – Breakthrough biomarker investigations and combined therapeutic approaches

Paris, June 27, 2014

On the topic of Precision Medicine against Cancer, the 6th WIN symposium was attended by over 400 people from over 35 countries to discuss the progress in this area and in particular on combined biomarkers and targeted therapeutic approaches. WIN 2014 brought together a panel of internationally renowned experts representing all sectors of personalized medicine in cancer research: academics, clinicians, pharmaceutical and biotechnology industries, life sciences, health informatics, regulatory bodies and patient groups.

For the 6th consecutive year, the American Society of Clinical Oncology (ASCO *), ESMO, EORTC, ESO and UICC have accredited the WIN symposium. All emphasized the high quality of the scientific program.

About WIN Consortium

WIN is an initiative from Gustave Roussy and University of Texas MDAnderson cancer center USA.

WIN is unique structurally in that it brings together organizations from academia, business and not-for-profit organizations to focus on translating the latest advances in personalized cancer medicine into the standard of care. WIN is built on the recognition that all stakeholders in personalized cancer therapy must collaborate and share information, in order to effectively bring the latest innovations in personalized cancer care to the patient. WIN is a non-profit organization formed by 40 renowned members: Academic cancer centers (25 centers in 16 countries), companies (Blue Cross Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health Services, Foundation Medicine, Millennium Takeda, AstraZeneca and Pfizer), non profit organisations such as EORTC, Fondation ARC and Sage Bionetworks.